[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"corneal-endothelial-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:corneal-endothelial-disorder":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,57],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100649041","phase-2-study-of-eo2002-in-subjects-with-corneal-edema-secondary-to-corneal-endothelial-dysfunction-100649041",false,"NCT07729137","Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction","A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 2 Study of EO2002 in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction (EMERALD)","EMERALD","Key Inclusion Criteria:\n\n1. Symptomatic central corneal edema that is primarily responsible for loss of vision associated with endothelial dysfunction which may be secondary to Fuchs corneal dystrophy or pseudophakic bullous keratopathy.\n2. Early Treatment Diabetic Retinopathy Study (ETDRS)-best-corrected distance visual acuity between 20 and 65 letters inclusive (≥ 20 and ≤ 65 letters)\n3. Central corneal thickness ≥ 600 μm and ≤ 1,000 μm, OR Medical Monitor review and approval based on either:\n\n   1. Historical CCT increased by ≥ 50 μm OR\n   2. Findings of edema by corneal tomography or Anterior Segment Optical Coherence Tomography (AS-OCT).\n4. Participant is considered a surgical candidate for full-thickness corneal transplantation or endothelial (partial thickness) keratoplasty (EK) consistent with standard-of-care indications.\n\nKey Exclusion Criteria:\n\n1. Corneal disease in either eye (other than corneal endothelial dysfunction secondary to Fuchs dystrophy or pseudophakic bullous keratopathy) including active or prior herpetic ocular infection, severe dry eye disease (e.g., Sjogren's), or active inflammation.\n2. Central corneal scarring from trauma, burns, or infection, or band keratopathy\n3. History of keratoconus or other corneal ectasia (e.g., keratoglobus and pellucid marginal degeneration).\n4. Visually significant cataract, that may limit the participant's ability to demonstrate treatment-related improvement in BCVA.\n5. Presence of an anterior chamber, sutured, or scleral-fixated intraocular lens.\n6. Presence of a multifocal or diffractive intraocular lens.\n7. Prior vitrectomy.\n8. Corneal refractive surgery.\n9. Descemet dettachment\n10. Minimally invasive glaucoma surgery (MIGS), intraocular pressure (IOP)- lowering implant (e.g., Durysta® or iDose®), or any incisional glaucoma surgery (e.g., trabeculectomy, glaucoma drainage implant).","ALL","21 Years",{"count":20,"type":21},121,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study will evaluate the safety and effectiveness of a single injection of EO2002 at one of two dose levels (150,000 or 500,000 magnetic human corneal endothelial cells \\[mHCECs\\]), compared with a placebo injection, in participants with corneal edema caused by corneal endothelial dysfunction.",[27,28,29,30,31,32,33,34,35,36,37,38],"Corneal Edema","Fuchs","Fuchs Dystrophy","Fuchs' Endothelial Dystrophy","Endothelial Corneal Dystrophy","Corneal Endothelial Decompensation","Corneal Endothelial Cell Loss","Corneal Endothelial Disorder","Corneal Endothelial Dystrophy 1","Endothelial Cell Loss, Corneal","Pseudophakic Bullous Keratopathy","Pseudophakic Bullous Keratopathy (PBK)",[40,41,42,29,28,43],"FECD","PBK","Corneal endothelial dysfunction","Corneal edema","NOT_YET_RECRUITING","2026-07-27",{"date":47,"type":48},"2026-07-29","ACTUAL",{"date":50,"type":21},"2026-09",{"date":52,"type":21},"2028-02",{"name":54,"class":55},"Emmecell","INDUSTRY",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":22,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":88},"100472805","the-belgian-endothelial-surgical-transplant-of-the-cornea-100472805","NCT05436665","The Belgian Endothelial Surgical Transplant of the Cornea","The Belgian Endothelial Surgical Transplant of the Cornea:Clinical and Patient-reported Outcomes of Descemet Stripping Automated Endothelial Keratoplasty(DSAEK) Versus Descemet Membrane Endothelial Keratoplasty(DMEK)","BESTCornea","Inclusion Criteria:\n\n* Fuchs Endothelial Dystrophy (FED);\n* Bullous Keratopathy (BK);\n* Other miscellaneous causes of endothelial dysfunction including decompensation of a previous corneal graft;\n* Pseudophakic (post cataract surgery);\n* Patients over 18 with the capacity to read and to understand the study information and to give informed consent, as well as study quality of life questionnaires;\n* Patients willing and capable to attend the 3, 6, and 12-month follow-up appointments.\n\nExclusion Criteria:\n\n* Inability to provide informed consent;\n* Patients unable to attend the proposed follow up;\n* Inclusion of the fellow eye in the study;\n* Complex surgery combined with multiple pathologies (i.e., glaucoma surgery);\n* Other contraindications to lamellar corneas surgery;\n* Patients who elect not to participate;\n* Patients under 18 years of age;\n* Patients that are currently pregnant or breastfeeding;\n* Phakic patients with no direct plan to perform cataract surgery.","18 Years",{"count":67,"type":21},220,[69],"NA","This study is designed as a randomised multicentric parallel group pragmatic trial of Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) versus Descemet Membrane Endothelial Keratoplasty (DMEK) in corneal endothelial decompensation. the purpose is to compare the clinical and patient reported outcomes of both therapies across a broad range of indications.",[27,34,30,72,37],"Bullous Keratopathy",[74,75,76],"DMEK","DSAEK","UT-DSAEK","RECRUITING","2026-03-30",{"date":80,"type":48},"2026-04-03",{"date":82,"type":48},"2022-08-10",{"date":84,"type":21},"2028-06-06",{"name":86,"class":87},"University Hospital, Antwerp","OTHER",11]